The HOME Core outcome set for clinical trials of atopic dermatitis
Hywel C Williams(University of Nottingham), Maarten Boers(Amsterdam University Medical Centers), Norito Katoh(Kyoto Prefectural University of Medicine), Laura Howells(University of Nottingham), Masutaka Furue(Kyushu University), Louise A. A. Gerbens(Amsterdam UMC Location University of Amsterdam), Jasvinder A. Singh(University of Alabama at Birmingham), Yael A. Leshem(Tel Aviv University), Joanne R Chalmers(University of Nottingham), Jochen Schmitt(University Hospital Carl Gustav Carus), Phyllis I. Spuls, Christian Apfelbacher(Heidelberg University), Eric L. Simpson(Oregon Health & Science University), Kim S Thomas(University of Nottingham)
Cited by 161
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
The Global Burden of Cancer 2013
|JAMA Oncology|2015|2.8k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k